Free Trial

Eli Lilly and Company (LLY) Stock Forecast & Price Target

Eli Lilly and Company logo
$772.57 -26.77 (-3.35%)
As of 02:18 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eli Lilly and Company - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
3
Buy
16

Based on 20 Wall Street analysts who have issued ratings for Eli Lilly and Company in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 1 has given a sell rating, 3 have given a hold rating, and 16 have given a buy rating for LLY.

Consensus Price Target

$1,012.56
31.06% Upside
According to the 20 analysts' twelve-month price targets for Eli Lilly and Company, the average price target is $1,012.56. The highest price target for LLY is $1,190.00, while the lowest price target for LLY is $700.00. The average price target represents a forecasted upside of 31.06% from the current price of $772.57.
Get the Latest News and Ratings for LLY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Eli Lilly and Company and its competitors.

Sign Up

LLY Analyst Ratings Over Time

TypeCurrent Forecast
7/15/24 to 7/15/25
1 Month Ago
6/15/24 to 6/15/25
3 Months Ago
4/16/24 to 4/16/25
1 Year Ago
7/16/23 to 7/15/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
16 Buy rating(s)
17 Buy rating(s)
17 Buy rating(s)
16 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
3 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$1,012.56$1,011.37$1,012.00$858.72
Forecasted Upside31.06% Upside23.55% Upside37.72% Upside-9.65% Downside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

LLY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LLY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Eli Lilly and Company Stock vs. The Competition

TypeEli Lilly and CompanyMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.80
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside26.65% Upside8,711.10% Upside10.67% Upside
News Sentiment Rating
Positive News

See Recent LLY News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/11/2025Guggenheim
2 of 5 stars
Seamus Fernandez
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$936.00 ➝ $942.00+19.21%
7/10/2025Morgan Stanley
3 of 5 stars
Terence Flynn
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$1,133.00 ➝ $1,135.00+43.19%
6/5/2025Erste Group Bank
3 of 5 stars
H. Engel
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
5/2/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Trung Huynh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$1,100.00 ➝ $1,050.00+27.26%
5/1/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight
4/28/2025HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Rajesh Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Reduce$1,150.00 ➝ $700.00-20.90%
4/28/2025Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Moderate Sell
4/22/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Carter Gould
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$975.00+19.17%
4/8/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Asad Haider
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$892.00 ➝ $888.00+20.24%
2/3/2025Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Srikripa Devarakonda
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$1,029.00 ➝ $1,038.00+27.51%
1/28/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Verdult
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$1,250.00 ➝ $1,190.00+47.25%
1/17/2025Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Andrew Berens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$950.00+8.68%
1/16/2025Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Kerry Holford
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$970.00+10.97%
12/10/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$997.00+24.17%
11/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$1,000.00+27.23%
11/4/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Baker
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
11/4/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$1,025.00 ➝ $1,015.00+25.66%
10/31/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$1,025.00 ➝ $975.00+16.30%
10/17/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Breen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$1,100.00+20.04%
9/13/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$1,050.00 ➝ $1,100.00+17.67%
9/5/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
U. Raffat
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
8/9/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$1,001.00 ➝ $1,101.00+30.36%
6/24/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$994.00 ➝ $1,015.00+12.98%
5/14/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$770.00 ➝ $840.00+11.04%
2/21/2024DZ Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$820.00+8.50%
8/9/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$490.00 ➝ $580.00+11.20%
8/8/2023Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$490.00 ➝ $580.00+11.20%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 02:18 PM ET.


Should I Buy Eli Lilly and Company Stock? LLY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, July 14, 2025. Please send any questions or comments about these Eli Lilly and Company pros and cons to contact@marketbeat.com.

Eli Lilly and Company
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Eli Lilly and Co:

  • The current stock price is around $799, reflecting a strong market position and investor confidence in the company's future growth.
  • Eli Lilly and Co reported a significant revenue increase of over 45% compared to the same quarter last year, indicating robust business performance and demand for its products.
  • The company has a high return on equity of over 85%, suggesting effective management and a strong ability to generate profits from shareholders' investments.
  • With a moderate buy consensus rating from analysts and an average price target of approximately $1,012, there is potential for stock appreciation.
  • The recent quarterly dividend of $1.50 per share, yielding about 0.75%, provides a steady income stream for investors, reflecting the company's commitment to returning value to shareholders.

Eli Lilly and Company
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Eli Lilly and Co for these reasons:

  • The company recently missed earnings expectations, reporting an EPS of $3.34 compared to the consensus estimate of $4.64, which may raise concerns about future profitability.
  • Despite strong revenue growth, the high P/E ratio of around 65 suggests that the stock may be overvalued, which could lead to price corrections.
  • Analysts have mixed ratings, with some downgrading their outlook, indicating uncertainty in the stock's future performance.
  • The company's debt-to-equity ratio of 2.18 indicates a higher level of debt compared to equity, which could pose risks in times of economic downturns.
  • Market volatility, as indicated by a beta of 0.40, suggests that the stock may not be as stable as some investors prefer, potentially leading to fluctuations in investment value.

LLY Forecast - Frequently Asked Questions

According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Eli Lilly and Company is $1,012.56, with a high forecast of $1,190.00 and a low forecast of $700.00.

20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and Company in the last year. There is currently 1 sell rating, 3 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LLY shares.

According to analysts, Eli Lilly and Company's stock has a predicted upside of 31.06% based on their 12-month stock forecasts.

Over the previous 90 days, Eli Lilly and Company's stock had 3 downgrades by analysts.

Eli Lilly and Company has been rated by research analysts at Cantor Fitzgerald, Erste Group Bank, Guggenheim, Hsbc Global Res, HSBC, Morgan Stanley, UBS Group, and Wells Fargo & Company in the past 90 days.

Analysts like Eli Lilly and Company less than other "medical" companies. The consensus rating score for Eli Lilly and Company is 2.75 while the average consensus rating score for "medical" companies is 2.81. Learn more on how LLY compares to other companies.


This page (NYSE:LLY) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners